Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
Why this trial matters: First large Phase III evidence of biopsy-confirmed histologic benefit with a metabolic drug in MASH Demonstrates semaglutides impact beyond weight loss to disease-modifying liver effects Supports expanding GLP-1 therapeutics into liver disease care amid a high unmet need Ianalumab Meets Endpoints in Phase III Sjgrens Disease Trials (NEPTUNUS-1 & 2) Novartis reported that both Phase III studies of ianalumab achieved their primary endpoints in patients with Sjgrens disease, offering the first targeted therapy with statistically significant disease activity reduction in this chronic autoimmune disorder
Figura 1
B12 has many functions in our body, so unfortunately a deficiency will give rise to a wide variety of symptoms, like brain fog, memory problems, cognitive impairment, insomnia, headaches, especially migraine, behavioural changes, learning problems, nominal aphasia, mood swings, irritability, depression, anxiety, hallucinations, delusions, psychosis, peripheral paraesthesia (pins and needles), numbness, neuropathic pains, poor balance, reduced vibration sense or proprioception (joint position sense), tinnitus, ataxia, taste impairment, sometimes myelopathy, fatigue, anaemia (either with larger red blood cells, or with normal size of the red blood cells when there is also iron deficiency), other reduction in blood cells, abdominal complaints, malabsorption, failure to thrive, weight loss, diarrhoea, hyperpigmentation, glossitis, (aphthous) stomatitis, infertility, urinary tract infections, joint and muscle pain, muscle weakness, spasticity, seizures, cardiomyopathy, urinary and/or faecal incontinence, postural hypotension/dizziness, erectile dysfunction, to name a few
Moreover, peroxynitrite modifies proteins by oxidation or nitration of tyrosine, tryptophan, methionine, and other amino acid residues (Bartesaghi and Radi 2018)
